209 filings
Page 9 of 11
8-K
jrxqfnn tlse
19 Jul 18
Other Events
6:59am
8-K
bb6uxtdnj7gfz9lw
13 Jul 18
Ovid Therapeutics Announces Initiation of Phase 2 ROCKET Clinical Trial to Evaluate OV101 in Fragile X Syndrome
9:22pm
EFFECT
aq27d6pundwgv3
20 Jun 18
Notice of effectiveness
12:15am
8-K
u7yrfvl 8rvx1opm0bu
11 Jun 18
Submission of Matters to a Vote of Security Holders
4:06pm
S-3
1489i2p
1 Jun 18
Shelf registration
5:14pm
8-K
wf1iqn
8 May 18
Results of Operations and Financial Condition
5:22pm
DEFA14A
p3xzy7
24 Apr 18
Additional proxy soliciting materials
12:00am
DEF 14A
7okvxu4ol1s j5r
24 Apr 18
Definitive proxy
12:00am
CT ORDER
shc4 eqwc
19 Apr 18
Confidential treatment order
12:00am
S-8
5utibum97tcu
29 Mar 18
Registration of securities for employees
12:00am
8-K
i9xu9knojsfobko
29 Mar 18
Ovid Therapeutics Reports Fourth Quarter and Full Year 2017 Financial
12:00am
10-K
bzzotz69bzdnr
29 Mar 18
Annual report
12:00am
8-K
m8us5dviit3l4jzhazjs
24 Jan 18
Departure of Directors or Certain Officers
12:00am
8-K
3uagu1f 7c6y29z0t
11 Dec 17
Ovid Therapeutics AnnouncesTAK-935/OV935 Has Received Orphan Drug Designation from U.S. FDA for Treatment of Dravet Syndrome
12:00am
8-K
90kkd
4 Dec 17
Ovid Therapeutics Announces OV101 Shows Comparable PK Profile in Phase
12:00am
8-K
2650znp rp
9 Nov 17
Ovid Therapeutics Reports Third Quarter 2017 Financial Results and Corporate Progress
12:00am
8-K
224ve0gw 5m80
16 Oct 17
Ovid Therapeutics Announces Positive Preclinical OV101 Data
12:00am
8-K
wz4l3ur6kbfx015i15z
10 Oct 17
Ovid Therapeutics Receives Orphan Drug Designation from the U.S. FDA for OV101 for Treatment of Fragile X Syndrome
12:00am